SRx Health Solutions, Inc.
Last · NYSE American$1.36-0.10 (-6.85%)stale · yahoo · 63h ago
Market cap$27.45M20.2M sh
P/E · TTM0.0fwd — · eps 62.19
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.96$42.60
Volume330.2Ksession
| Revenue | $6.5M |
|---|---|
| Operating income | $-11.4M |
| Net income | $-45.0M |
| Operating margin | -174.6% |
| Net margin | -688.8% |
| Return on equity | -11058.0% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2025-12-05
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Sbc Revenue High — SBC/Revenue 49.1%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -688.8%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -124.6%
- Cash Runway Low — Cash runway ~0.2 years
- Accumulated Deficit High — Accumulated deficit / equity 5633%
Press & signals
- GlobeNewswire
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform
- GlobeNewswire
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
- GlobeNewswire
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags